Full Press Release Details
CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales
Winter Springs, Florida, January 7, 2020 - iRadimed
Corporation (NASDAQ: IRMD) announced the retirement of Brent Johnson, Executive Vice President of Worldwide Sales and Marketing,
effective April 10, 2020 after leading the Company's commercial efforts since 2012. iRadimed
appointed MaryBeth Smith as Vice President of Worldwide Sales, succeeding Mr. Johnson, effective January 20, 2020. Ms. Smith will
report to Leslie McDonnell, President and Chief Executive Officer.
"Under Brent's leadership, iRadimed
achieved compound annual sales growth of 26% by significantly expanding its U.S. sales force and international distributor
network and entering new markets. We would like to congratulate Brent on his retirement and thank him for his many contributions
and commitment to a successful transition," said McDonnell.
"MaryBeth has a strong track record of delivering sales
growth, customer retention and market expansion. I am confident MaryBeth will do a fantastic job of building upon our past success
and helping lead the Company into the future. We are excited to add her to the executive team," said McDonnell.
About MaryBeth Smith
Ms. Smith has extensive commercial experience with medical technology
products. Prior to her appointment at iRadimed, Ms. Smith spent more than 20 years
at Natus Medical, Inc., most recently as the Vice President of Sales and Sales Operations for newborn care products. Prior to that,
Ms. Smith held a number of leadership and operational roles at Natus where she successfully introduced and established new products
as a standard of care. Ms. Smith earned a Bachelor of Science in Nursing from Viterbo University.
About iRadimed Corporation
iRadimed Corporation
is a leader in the development of innovative magnetic resonance imaging ("MRI") compatible medical devices.
We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system that is specifically designed
to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many
of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which
can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI
system. Our patented MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor,
uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids
during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid
delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital
medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special features to safely and accurately monitor a patient's vital
signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which
means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it
to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted
vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features
of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo algorithms; non-magnetic
respiratory CO2; non-invasive blood pressure; invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic
agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs
monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information please visit www.iradimed.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Act of 1995, particularly statements regarding our expectations, beliefs, plans, intentions,
future operations, financial condition and prospects, and business strategies. These statements relate to future events or our
future financial performance or condition and involve unknown risks, uncertainties and other factors that could cause our actual
results, level of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking
statements. The risks and uncertainties referred to above include, but are not limited to, risks associated with the Company's
ability to receive an EC Certificate or CE Mark for our existing products, receive FDA 510(k) clearance for new products; unexpected
costs, delays or diversion of management's attention associated with the design, manufacture or sale of new products; the
Company's ability to implement successful sales techniques for existing and future products and evaluate the effectiveness
of its sales techniques; additional actions, warnings or requests from the FDA; our significant reliance on a single product; potential
disruptions in our limited supply chain for our products; a reduction in international distribution; actions of the FDA or other
regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient
adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of
new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations.
Further information on these and other factors that could affect
the Company's financial results is included in filings we make with the Securities and Exchange Commission from time to time.
All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update
forward-looking statements.
Chief Financial Officer
iRadimed Corporation